Key Points
- Director Michael Patrick Miller sold 20,000 shares on Nov. 11 at an average price of $4.86 for $97,200, cutting his position by 27.03% to 54,000 shares (SEC filing).
- Puma reported quarterly EPS of $0.21 vs. $0.09 expected and revenue of $54.48M vs. $51M estimated, with strong profitability metrics (ROE 53.15%, net margin 20.38%).
- The stock trades near $4.97 with a $250M market cap, P/E ~5.1 and a 12‑month range of $2.32–$6.12, while analysts' consensus is a "Moderate Buy" with a $7.00 target.
Puma Biotechnology, Inc. (NASDAQ:PBYI - Get Free Report) Director Michael Patrick Miller sold 20,000 shares of the stock in a transaction that occurred on Tuesday, November 11th. The shares were sold at an average price of $4.86, for a total value of $97,200.00. Following the transaction, the director owned 54,000 shares in the company, valued at $262,440. This trade represents a 27.03% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.
Puma Biotechnology Price Performance
NASDAQ PBYI traded up $0.02 during mid-day trading on Friday, hitting $4.97. The stock had a trading volume of 199,145 shares, compared to its average volume of 500,963. The company has a debt-to-equity ratio of 0.10, a current ratio of 1.73 and a quick ratio of 1.62. The firm's 50 day moving average is $5.01 and its 200 day moving average is $4.16. Puma Biotechnology, Inc. has a twelve month low of $2.32 and a twelve month high of $6.12. The stock has a market capitalization of $250.09 million, a price-to-earnings ratio of 5.08 and a beta of 1.35.
Puma Biotechnology (NASDAQ:PBYI - Get Free Report) last posted its quarterly earnings results on Thursday, November 6th. The biopharmaceutical company reported $0.21 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.09 by $0.12. The company had revenue of $54.48 million for the quarter, compared to analyst estimates of $51.00 million. Puma Biotechnology had a return on equity of 53.15% and a net margin of 20.38%. Puma Biotechnology has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS. Equities research analysts forecast that Puma Biotechnology, Inc. will post 0.31 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Puma Biotechnology
A number of institutional investors have recently modified their holdings of the business. BNP Paribas Financial Markets raised its holdings in shares of Puma Biotechnology by 39.7% during the third quarter. BNP Paribas Financial Markets now owns 8,056 shares of the biopharmaceutical company's stock valued at $43,000 after buying an additional 2,290 shares during the last quarter. CWM LLC increased its position in shares of Puma Biotechnology by 214.1% in the second quarter. CWM LLC now owns 9,462 shares of the biopharmaceutical company's stock worth $32,000 after acquiring an additional 6,450 shares in the last quarter. Cerity Partners LLC purchased a new stake in shares of Puma Biotechnology in the second quarter valued at $36,000. Caprock Group LLC acquired a new position in shares of Puma Biotechnology in the 3rd quarter valued at about $59,000. Finally, Perkins Capital Management Inc. acquired a new stake in shares of Puma Biotechnology during the 3rd quarter valued at $65,000. Institutional investors own 61.29% of the company's stock.
Analyst Ratings Changes
Several equities research analysts recently weighed in on the company. Wall Street Zen downgraded Puma Biotechnology from a "strong-buy" rating to a "buy" rating in a report on Saturday, November 8th. Weiss Ratings lowered shares of Puma Biotechnology from a "buy (b-)" rating to a "hold (c+)" rating in a research note on Saturday, October 25th. One equities research analyst has rated the stock with a Buy rating and one has assigned a Hold rating to the company's stock. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $7.00.
Get Our Latest Analysis on Puma Biotechnology
Puma Biotechnology Company Profile
(
Get Free Report)
Puma Biotechnology, Inc, a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
